Exelixis IncEXEL
Price$57.94Intrinsic value$75.9131% above price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $75.91median of 6 methods · middle span $34-$262based on filings through 3 Jul 2026
Market Price $57.94Price as of 1 Oct 2026
Margin of Safety +31.0%as of 1 Oct 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 15.3% (near-term consensus, capped) · years 2–5: 14.6%/yr (balance of the path).14.8% per year
Years 6–10: glide to demonstrated growth own history 24.6%, capped at 20%
Per-year rates
Yr 614.6%Yr 714.7%Yr 814.7%Yr 914.7%Yr 1014.8%
14.6% → 14.8%
Years 11–20: glide to long-run rate
Per-year rates
Yr 1113.6%Yr 1212.4%Yr 1311.2%Yr 1410.1%Yr 158.9%Yr 167.7%Yr 176.5%Yr 185.4%Yr 194.2%Yr 203.0%
14.8% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 2 windows (5/6y) (limited history)24.6%
Discount rate (cost of equity) 7.7%
Volatility vs market (adjusted beta)0.61

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetExelixis IncEXELHealth Care
Valuation
P/E18.2×
P/S6.0×
P/B8.2×
EV / Revenue5.8×
EV / EBITDA12.2×
Profitability
Gross margin96.7%
Operating margin42.3%
Net margin35.3%
FCF margin48.1%
Returns
ROE46.7%
ROA34.5%
ROIC—
Growth
Revenue growth (YoY)12.3%
5-yr fwd EPS growth14.8%
Financial strength
Debt / Equity—
Current ratio3.46×
Altman Z-Score15.8
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.